Physician profile
Brian B Lo
NPI 1073501565
$1,756.80
in general payments reported to CMS, 2019-2025
28 companies · $19.12 in 2025
The $19.12 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $890 · 2021: $214 · 2024: $18.35 · 2025: $19.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $241.81 | 2020-2025 | Prolia, Evenity |
| Novo Nordisk INC | $166.46 | 2020-2021 | |
| Amarin Pharma, INC. | $149.10 | 2020 | |
| Genentech USA, INC. | $124.88 | 2019 | |
| Grifols USA, LLC | $114.82 | 2019 | |
| Abbvie INC. | $100.29 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.18 | 2019 | |
| Ibsa Pharma INC. | $75.66 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $69.02 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $59.00 | 2019 | |
| Allergan, INC. | $57.87 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $54.34 | 2020 | |
| Merck Sharp & Dohme LLC | $51.76 | 2020-2021 | |
| Pfizer INC. | $51.62 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $42.57 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $35.50 | 2020 | |
| Janssen Pharmaceuticals, INC | $35.41 | 2019 | |
| Corcept Therapeutics | $33.09 | 2020 | |
| Glaxosmithkline, LLC. | $29.89 | 2019 | |
| Shire North American Group INC | $26.01 | 2019 | |
| Mannkind Corporation | $24.18 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $19.76 | 2019 | |
| Mylan Specialty L.P. | $18.98 | 2019 | |
| Linus Health, INC. | $18.35 | 2024 | Core Cognitive Evaluation |
| Endo Pharmaceuticals INC. | $16.10 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.69 | 2019 | |
| Esperion Therapeutics, INC. | $15.26 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.